Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 260988
                    [Title] => Preventing diabetes
                    [Summary] => The antihypertensive valsartan can prevent the onset of diabetes among high-risk patients with elevated blood pressure, based on the findings of the new landmark trial VALUE (Valsartan Antihypertensive Long-term Use Evaluation).


Controlling blood sugar level and blood pressure is crucial for hypertensive patients because these can lead to serious consequences if left untreated.


High blood pressure or hypertension is a widespread medical condition with severe complications, including kidney disease and heart failure. 


                    [DatePublished] => 2004-08-12 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 237722
                    [Title] => Results of landmark heart study bared
                    [Summary] => More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that researchers hope will change the medical landscape in the management of heart diseases.


Results of VALIANT (Valsartan in Acute Myocardial Infarction Trial) was presented to doctors from all over the country by Prof. Inder Anand, chief of the Cardiology Section of the Veterans Affair Medical Center in Minneapolis, USA. 


                    [DatePublished] => 2004-02-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 236012
                    [Title] => Landmark trial shows benefits of ‘valsartan’
                    [Summary] => Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor blocker (ARB) family, is as effective as the ACE-inhibitor captopril in reducing the risk of death and other non-fatal cardiovascular events (CV) among high-risk patients, as results of the VALIANT study show.


                    [DatePublished] => 2004-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

VALSARTAN

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 260988
                    [Title] => Preventing diabetes
                    [Summary] => The antihypertensive valsartan can prevent the onset of diabetes among high-risk patients with elevated blood pressure, based on the findings of the new landmark trial VALUE (Valsartan Antihypertensive Long-term Use Evaluation).


Controlling blood sugar level and blood pressure is crucial for hypertensive patients because these can lead to serious consequences if left untreated.


High blood pressure or hypertension is a widespread medical condition with severe complications, including kidney disease and heart failure. 


                    [DatePublished] => 2004-08-12 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 237722
                    [Title] => Results of landmark heart study bared
                    [Summary] => More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that researchers hope will change the medical landscape in the management of heart diseases.


Results of VALIANT (Valsartan in Acute Myocardial Infarction Trial) was presented to doctors from all over the country by Prof. Inder Anand, chief of the Cardiology Section of the Veterans Affair Medical Center in Minneapolis, USA. 


                    [DatePublished] => 2004-02-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 236012
                    [Title] => Landmark trial shows benefits of ‘valsartan’
                    [Summary] => Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor blocker (ARB) family, is as effective as the ACE-inhibitor captopril in reducing the risk of death and other non-fatal cardiovascular events (CV) among high-risk patients, as results of the VALIANT study show.


                    [DatePublished] => 2004-01-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Preventing diabetes

August 12, 2004 - 12:00am

The antihypertensive valsartan can prevent the onset of diabetes among high-risk patients with elevated blood pressure, based on the findings of the new landmark trial VALUE (Valsartan Antihypertensive Long-term...

Science and Environment

Results of landmark heart study bared

February 5, 2004 - 12:00am

More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that...

Science and Environment

Landmark trial shows benefits of ‘valsartan’

January 22, 2004 - 12:00am

Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor...

Science and Environment